· The Phase 2 trial is an important step in the dual product development of ZP4207: both as a rescue pen to treat severe hypoglycemia and as an essential component in an artificial pancreas device for better diabetes control
· Advancing ZP4207 into Phase 2 development is in line with Zealand’s strategic focus on growing its pipeline of proprietary peptide medicines for accelerated value creation
· Trial completion and results are expected in H2 2016
Copenhagen, 4 February 2016 – Zealand informs that the first patients have successfully been dosed in a Phase 2 trial with ZP4207 for the treatment and control of hypoglycemia associated with diabetes. ZP4207 is a novel stable glucagon analogue for liquid formulation, invented and fully owned by Zealand.
